SynthesisCancer medicine2019

Nivolumab provides improved effectiveness and safety compared with docetaxel as a second-line treatment for advanced non-small cell lung cancer: A systematic review and meta-analysis.

Zheng Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.